Published

Psychedelics for treatment of negative symptoms and depressive symptoms in schizophrenia spectrum disorder: A narrative review.

An abstract is available from the original source but is not redistributed by this tracker. Read the source record.

Open source BibTeX RIS

Bibliographic context

Journal: Schizophrenia research
Date: 2026-06-01
Source: PubMed
DOI: 10.1016/j.schres.2026.03.003
PubMed: 41830808

Derived topics and classifications

psilocybin Depression Neuroplasticity Receptor Pharmacology Default Mode Network Review Article Case Report Animal Study Treatment-Resistant Depression Safety Clinical Trial

Citation graph

0 referenced DOIs found in stored source metadata. 0 indexed papers cite this DOI.

Open citation network

Related papers

Psychedelics and mental health: reimagining care through science, insight, and compassion.Frontiers in pharmacology · 2025-01-01 Psychedelic renaissance: A renewed focus on the clinical utility of hallucinogensPsychiatry and Clinical Neurosciences Reports · 2024-05-16 Contribution of the Serotonin 5-HT2A Receptor to the Therapeutic Effect of Psilocin on Social Behavior Deficits in Mice Repeatedly Exposed to Social Defeat StressNeuropsychopharmacology Reports · 2026-09-01 Psilocybin and the glutamatergic pathway: implications for the treatment of neuropsychiatric diseases.Pharmacological reports: PR · 2024-12-01 Psychedelic-assisted therapy for palliative care within a home treatment setting: A case report.Clinical case reports · 2024-09-01 Cardiovascular safety of psychedelic medicine: current status and future directions.Pharmacological reports: PR · 2023-12-01 Pharmacotherapeutic Management of Depression in Patients With Cancer: A Review of Mechanistic and Clinical Evidence.Cancer reports (Hoboken, N.J.) · 2026-05-01 A comparative assessment of the antidepressant efficacy of ketamine, psilocybin, and fluoxetine in a chronic stress model.Scientific reports · 2025-11-26